New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
- Details
- Category: Product
Schering-Plough Corporation (NYSE: SGP) has announced the introduction of new CLARITIN(R) Liqui-Gels(R), the first and only non-drowsy allergy medicine in an easy-to-swallow liquid-filled capsule. Now available over-the-counter, CLARITIN(R) Liqui-Gels(R) provide powerful liquid relief for the worst allergy symptoms without causing drowsiness.
Pfizer Receives FDA Complete Response Letter for Lasofoxifene
- Details
- Category: Pfizer
Pfizer Inc said today it has received a complete response letter from the U.S. Food and Drug Administration (FDA) asking for additional information on the company's application for lasofoxifene. The investigational compound is currently under review for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
US Department of Health and Human Services awards Novartis USD 486 million contract
- Details
- Category: Novartis
The US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS, BARDA) has awarded Novartis Vaccines a contract for up to USD 486 million over eight years to support the design, construction, validation, and licensing of U.S. cell-based influenza vaccine manufacturing facilities in Holly Springs, North Carolina, to provide a pre-pandemic supply of influenza vaccine and to provide the capacity to manufacture 150 million doses of pandemic vaccine within six months of declaration of an influenza pandemic.
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) today announced that it has reached resolution with the United States Attorney for the Eastern District of Pennsylvania (EDPA) and the Office of Consumer Litigation of the Department of Justice regarding the previously-reported government investigation into the company's past U.S. marketing and promotional practices for the antipsychotic medication Zyprexa(R) (olanzapine).
Nycomed strengthens its osteoporosis portfolio
- Details
- Category: Nycomed
Nycomed and EffRx have announced a licensing agreement on EffRx' drug EX101 (effervescent alendronate) for the treatment of osteoporosis. Under the agreement, Nycomed will receive the exclusive rights to develop, manufacture and commercialise the effervescent formulation of alendronate for the treatment of osteoporosis in a large number of countries worldwide. EX101 presents a significant enhancement to Nycomed's osteoporosis portfolio.
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM)
- Details
- Category: Product
Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS(TM) (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.
Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection
- Details
- Category: Abbott
European clinicians will have a new weapon to combat cervical cancer with the introduction of Abbott Molecular's real-time polymerase chain reaction (PCR) based diagnostic test for human papillomavirus (HPV). The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer.
More Pharma News ...
- Genzyme and Isis Begin New Clinical Trials of Mipomersen
- GlaxoSmithKline successfully completes tender offer for shares of Genelabs Technologies, Inc.
- U.S. Patent and Trademark Office Accepts Pfizer's Reissue Application on Lipitor
- Novo Nordisk and VLST Corporation announce collaboration agreement
- GlaxoSmithKline to cease providing corporate political contributions
- Glivec shows significant benefit for gastrointestinal stromal tumor (GIST) patients
- AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration